The Genetic Data Market: Institutional Governance of Academic/Industry Research Partnerships for the Public Good.
The Trump Administration's cuts to research funding and opposition to diversity, equity, and inclusion is destabilizing academic research. These attacks coincide with pointed government support for the private sector. But the conceptualization of academic versus private sector health research has hi...
| Publicado en: | American Journal of Bioethics Vol. 25; no. 12; pp. 4 - 19 |
|---|---|
| Autor principal: | |
| Formato: | Journal Article |
| Publicado: |
Taylor & Francis Ltd
Dec2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189411491&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 189411491 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15265161 FKZ jtl: American Journal of Bioethics issn: 15265161 maglogo: N pubinfo: dt: Dec2025 vid: 25 iid: 12 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 189411491 188144282 10.1080/15265161.2025.2554770 189411491 ppf: 4 ppct: 15 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: The Genetic Data Market: Institutional Governance of Academic/Industry Research Partnerships for the Public Good. aug: au: Spector-Bagdady, Kayte affil: University of Michigan sug: subj: Organizational Culture Collaboration Professional Organizations Research, Medical United States Genomics Academic Medical Centers Health Care Industry Financing, Government Research Support Private Sector Politics Decision Making, Organizational Health Policy Diversity, Equity, Inclusion United States Collective Bargaining Data Security Negotiation ab: The Trump Administration's cuts to research funding and opposition to diversity, equity, and inclusion is destabilizing academic research. These attacks coincide with pointed government support for the private sector. But the conceptualization of academic versus private sector health research has historically been a false binary. Drawing on mixed methods research, this paper examines the genomic data market as an example of advantages and challenges of commercializing academic expertise. It also highlights the structural downsides of researchers individually navigating industry partnerships. While academia is currently being put in the unenviable position of being more likely to need the private sector to conduct research, with less federal funding to offer in exchange, structural pain points have existed for decades. This is an opportunity for academia to harness its powers of expertise and collective action to develop institutional policy to ensure academic/industry research is beneficial to the public health and diverse patient communities. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|